Staying private or going public? Which is best…. the view from the top?

Access to capital and liquidity are important factors for C suite and investors alike. However going public comes with a different set of pressures – regulatory, communication demands etc.

This session will address both private and public CEOs to ask what lessons have been learned and if they would do it all again.


PRIYA MANDE | Chief Operating Officer | PsiOxus Therapeutics


CLIVE DIX | Chief Executive Officer | C4X Discovery
STEVE HARRIS | Chairman | Synchrony Pharma
THEODORA HAROLD | Chief Executive Officer | Crescendo Biologics
JOHN DAWSON | Chief Executive Officer | Oxford Biomedica
ALLAN MARCHINGTON | Managing Partner & Senior Advisor | Bridge Valley Ventures & Apposite Capital